诺瓦瓦克斯医药（NVAX）今日盘前大跌5.03%，引发市场关注。
消息面上，美国银行对诺瓦瓦克斯医药的评级和目标价进行了下调。美银将诺瓦瓦克斯医药的评级从"中性"下调至"跑输大市"，同时将目标价从9美元下调至7美元。这一评级调整显然对投资者信心造成了打击，导致股价在盘前交易中大幅下挫。
美银此次下调评级和目标价可能反映了对诺瓦瓦克斯医药未来业务前景的担忧。作为一家生物技术公司，诺瓦瓦克斯医药的股价往往对市场情绪和分析师评级变化较为敏感。此次评级下调可能会引发更多投资者重新评估该公司的投资价值，短期内可能会给股价带来进一步压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.